米力农联合参麦注射液治疗肺心病心衰患者的临床效果

Clinical effect of milrinone combined with Shenmai Injection on patients with pulmonary heart disease and heart failure

目的分析并研究米力农联合参麦注射液治疗肺源性心脏病(肺心病)心力衰竭(心衰)患者的临床效果。方法60例肺心病心衰患者,通过电脑随机筛选的方式将所有患者分为观察组与对照组,每组30例。对照组给予常规治疗,观察组患者在常规治疗的基础上给予米力农联合参麦注射液进行治疗。比较两组临床疗效以及治疗前后的血气指标[动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)]、肺功能指标[肺活量(VC)、用力肺活量(FVC)与第1秒用力呼气容积(FEV1)]水平。结果治疗后,观察组治疗总有效率96.67%高于对照组的70.00%,差异具有统计学意义(P<0.05)。治疗后,观察组PaO2(9.87±1.79)kPa高于对照组的(6.57±0.54)kPa,PaCO2(6.13±1.02)kPa低于对照组的(8.79±1.68)kPa,差异均具有统计学意义(t=9.667、7.413,P=0.000、0.000<0.05)。治疗后,两组患者肺功能均有所改善,其中观察组患者VC为(2.96±0.67)L、FVC为(2.67±0.87)L、FEV1为(1.87±0.58)L,均高于对照组的(1.78±0.57)、(1.54±0.24)、(1.54±0.24)L,差异均具有统计学意义(t=7.347、6.858、2.880,P=0.000、0.000、0.006<0.05)。结论应用米力农联合参麦注射液对肺心病心衰患者进行治疗,可以取得显著的疗效,能够有效地改善患者的心肺功能,值得临床推广与研究。

Objective To analyze and study the clinical effect of milrinone combined with Shenmai Injection on patients with pulmonary heart disease and heart failure.Methods A total of 60 patients with pulmonary heart disease and heart failure were randomly divided into observation group and control group,with 30 cases in each group.The control group was treated with conventional therapy,and the observation group was treated with milrinone and Shenmai Injection on the basis of conventional therapy.Both groups were compared in terms of clinical efficacy,blood gas indicators[arterial partial pressure of oxygen(PaO2),arterial partial pressure of carbon dioxide(PaCO2)],pulmonary function indicators[vital capacity(VC),forced vital capacity(FVC)and forced expiratory volume in the 1st second(FEV1)]before and after treatment.Results After treatment,the total effective rate 96.67%of the observation group was higher than 70.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,PaO2(9.87±1.79)kPa in the observation group was higher than(6.57±0.54)kPa in the control group,and PaCO2(6.13±1.02)kPa was lower than(8.79±1.68)kPa in the control group.All the differences were statistically significant(t=9.667,7.413;P=0.000,0.000<0.05).After treatment,the pulmonary function of the two groups was improved.Among them,the observation group had VC of(2.96±0.67)L,FVC of(2.67±0.87)L,and FEV1 of(1.87±0.58)L,which were higher than(1.78±0.57),(1.54±0.24)and(1.54±0.24)L of the control group,and the differences were statistically significant(t=7.347,6.858,2.880;P=0.000,0.000,0.006<0.05).Conclusion Combination of milrinone and Shenmai Injection has significant efficacy on patients with pulmonary heart disease and heart failure,and it can effectively improve the cardiopulmonary function of patients,which is worthy of clinical promotion and research.